Conditions: Chemotherapy-induced Nausea and Vomiting
Keywords: chemotherapy nausea vomiting
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 120
Healthy volunteers: no

Brief summary:
The purpose of the study is to mainly evaluate the efficacy and safety of aprepitant in combination with olanzapine ,palonosetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly or moderately emetogenic chemotherapy.

Detailed description:
Eligible patients will be randomized to receive different antiemetic regimens . In the experimental group,patients will receive aprepitant,olanzapine ,palonosetron and dexamethasone .In the other group,patients will accept the same dose of aprepitant ,palonosetron and dexamethasone .During the treatment, any grade of nausea and vomiting should be recorded in order to evaluate the complete response rate of CINV,nausea patients will be measured by a visual analogue scale (VAS) ,other adverse events should be recorded as well.

Arms:
arm 1: Olanzapine in combination with aprepitant ,palonosetron and dexamethasone. arm 2: Aprepitant in combination with palonosetron and dexamethasone

Interventions: intervention 1: Olanzapine intervention 2: Aprepitant intervention 3: Palonosetron intervention 4: Dexamethasone
Intervention descriptions: intervention 1: 5mg,twice a day orally on day 1 to day 4 intervention 2: 125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3. intervention 3: 0.25mg IV 30-60min before chemotherapy on day 1 intervention 4: 6mg IV on day 1 ，3.75mg IV on day 2 to 4

Protocol document: